ATP-Loaded Liposomes Effectively Protect the Myocardium in Rabbits with an Acute Experimental Myocardial Infarction

Verma, Daya D.; Hartner, William C.; Levchenko, Tatyana; Bernstein, Eugene A.; Torchilin, Vladimir P.

doi:10.1007/s11095-005-8354-x

Cited by 56 publications

(47 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intracoronary infusion of nontargeted ATP-loaded liposomes before regional ischemia-reperfusion injury resulted in a significant reduction in infarct size as compared with controls in a rabbit model. 23 One possible limitation of these studies is that drug-loaded nanocarriers were administered prior to ischemia instead of being administered at the end of ischemia or at the early stage of reperfusion. It seems justified that accumulation of nanoparticles in the myocardium is most intensive at the time of reperfusion.…”

Section: Discussionmentioning

confidence: 99%

Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles

Galagudza¹,

Королев²,

Постнов³

et al. 2012

IJN

View full text Add to dashboard Cite

Pharmacological agents suggested for infarct size limitation have serious side effects when used at cardioprotective doses which hinders their translation into clinical practice. The solution to the problem might be direct delivery of cardioprotective drugs into ischemic-reperfused myocardium. In this study, we explored the potential of silica nanoparticles for passive delivery of adenosine, a prototype cardioprotective agent, into ischemic-reperfused heart tissue. In addition, the biodegradation of silica nanoparticles was studied both in vitro and in vivo. Immobilization of adenosine on the surface of silica nanoparticles resulted in enhancement of adenosine-mediated infarct size limitation in the rat model. Furthermore, the hypotensive effect of adenosine was attenuated after its adsorption on silica nanoparticles. We conclude that silica nanoparticles are biocompatible materials that might potentially be used as carriers for heart-targeted drug delivery.

show abstract

Section: Discussionmentioning

confidence: 99%

Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles

Galagudza¹,

Королев²,

Постнов³

et al. 2012

IJN

View full text Add to dashboard Cite

show abstract

“…In particular, anti-myosin monoclonal antibody-doped liposomes containing ATP were administered to the isolated rat heart prior to global ischemia-reperfusion (Verma et al, 2006), which was associated with better postischemic contractile recovery. Intracoronary infusion of non-targeted ATPloaded liposomes before regional ischemia-reperfusion resulted in significant reduction in infarct size as compared to controls in rabbit model (Verma et al, 2005). One possible limitation of these studies is that drug-loaded nanocarriers were administered prior to ischemia instead of administering at the end of ischemia or at the early stage of reperfusion.…”

Section: Heart Targeting With Nanoparticulate Carriersmentioning

confidence: 99%

Cardiac Protection with Targeted Drug Delivery to Ischemic-Reperfused Myocardium

Galagudza¹

2012

Novel Strategies in Ischemic Heart Disease

View full text Add to dashboard Cite

“…The procedure described elsewhere 31 was followed with modifications. Rats were anesthetized with ketamine (80 mg/kg) and xylazine (8 mg/kg).…”

Section: In Vivo Study With Emi Model In Ratsmentioning

confidence: 99%

Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide

Hartner

Kale

et al. 2008

Gene Ther

View full text Add to dashboard Cite

The treatment of myocardial ischemia using gene therapy is a rather novel but promising approach. Gene delivery to target cells may be enhanced by using double-targeted delivery systems simultaneously capable of extracellular accumulation and intracellular penetration. With this in mind, we have used low cationic liposomes-plasmid DNA complexes (lipoplexes) modified with cell-penetrating transactivating transcriptional activator (TAT) peptide (TATp) and/or with monoclonal anti-myosin monoclonal antibody 2G4 (mAb 2G4) specific toward cardiac myosin, for targeted gene delivery to ischemic myocardium. In vitro transfection of both normoxic and hypoxic cardiomyocytes was enhanced by the presence of TATp as determined by fluorescence microscopy and ELISA. The in vitro transfection was further enhanced by the additional modification with mAb 2G4 antibody in the case of hypoxic, but not normoxic cardiomyocytes. However, we did not observe a synergism between TATp and mAb 2G4 ligands under our experimental condition. In in vivo experiments, we have clearly demonstrated an increased accumulation of mAb 2G4-modified TATp lipoplexes in the ischemic rat myocardium and significantly enhanced transfection of cardiomyocytes in the ischemic zone. Thus, the genetic transformation of normoxic and hypoxic cardiomyocytes can be enhanced by using lipoplexes modified with TATp and/or mAb 2G4. Such complexes also demonstrate an increased accumulation in the ischemic myocardium and effective transfection of

show abstract

ATP-Loaded Liposomes Effectively Protect the Myocardium in Rabbits with an Acute Experimental Myocardial Infarction

Cited by 56 publications

References 25 publications

Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles

Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles

Cardiac Protection with Targeted Drug Delivery to Ischemic-Reperfused Myocardium

Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide

Contact Info

Product

Resources

About